Native arteriovenous fistula (AVF) accounts for the majority of vascular access for hemodialysis (HD) patients in Taiwan. Vascular access dysfunction causes significant clinical morbidity in HD patients. Venous stenosis that results from neointimal hyperplasia is the most common cause of vascular access dysfunction in an AVF. The exact molecular mechanisms underlying the formation of venous stenosis in AVF failure are poorly understood. Many molecular pathways that are associated with oxidative stress, inflammation, angiogenesis and endothelial dysfunction have been hypothesized to cause progressive venous stenos is. Although many studies have implicated the venous stenosis mechanism, few strategies can effectively prevent vascular access failure in HD patients. This review describes the important molecular pathways for hemodialysis access stenosis and presents potential preventive therapies for AVF failure. It is hoped that this paper will lead to effective preventive treatments for AVF dysfunction in the future.